Patents by Inventor Roger Barraclough

Roger Barraclough has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies to an epitope of AGR2, assays and hybridomas
    Patent number: 8329875
    Abstract: Provided is a monoclonal antibody, or an antigen binding fragment thereof, which binds specifically to an epitope within the sequence KPGAKKDTKDSRPKL (Sequence ID No. 2) of AGR2. Such monoclonal antibodies are of prognostic and diagnostic utility in the investigation of cancer, particularly metastatic cancer. The antibodies described may also be used in prognosis or diagnosis of inflammatory diseases. Also provided are kits and solid supports comprising such antibodies, as well as the therapeutic use of antibodies of the invention.
    Type: Grant
    Filed: August 28, 2007
    Date of Patent: December 11, 2012
    Assignee: The University Of Liverpool
    Inventors: Roger Barraclough, Dong Liu Barraclough, Philip Rudland
  • ANTIBODIES TO AN EPITOPE OF AGR2, ASSAYS AND HYBRIDOMAS
    Publication number: 20110052586
    Abstract: Provided is a monoclonal antibody, or an antigen binding fragment thereof, which binds specifically to an epitope within the sequence KPGAKKDTKDSRPKL (Sequence ID No. 2) of AGR2. Such monoclonal antibodies are of prognostic and diagnostic utility in the investigation of cancer, particularly metastatic cancer. The antibodies described may also be used in prognosis or diagnosis of inflammatory diseases. Also provided are kits and solid supports comprising such antibodies, as well as the therapeutic use of antibodies of the invention.
    Type: Application
    Filed: August 28, 2007
    Publication date: March 3, 2011
    Applicant: The University of Liverpool
    Inventors: Roger Barraclough, Dong Liu Barraclough, Philip Rudland
  • System and method for providing a waveform for stimulating biological tissue
    Patent number: 7715912
    Abstract: An implantable programmable stimulator system includes memory that stores at least one waveform. A playback system provides an output waveform based on retrieving the at least one waveform from the memory. An output system is configured to drive at least one output channel based on the output waveform, the output system selecting the at least one output channel from a plurality of output channels in response to a selection signal.
    Type: Grant
    Filed: September 15, 2006
    Date of Patent: May 11, 2010
    Assignees: Intelect Medical, Inc., The Cleveland Clinic Foundation
    Inventors: Ali R. Rezai, Keith Richard Carlton, Scott Gordon Leyh, Steven E. Wilder, Roger Barraclough Fell
  • Conditionally immortalized cell lines derived from transgenic animals
    Patent number: 6825394
    Abstract: The invention relates to mammalian cell lines and transgenic mammals. More particularly, it relates to a method for producing a rat cell line, a method for producing a transgenic rat, a transgenic rat, a rat cell line, cells and tissue obtained therefrom and uses therefore. The cell line derived from a transgenic mammal comprises: (i) a conditional oncogene, transforming gene or immortalising gene or a cell cycle affecting gene; and (ii) a cell type specific promoter. They include a neuronal cell line in which the cell type specific promoter is an NF-L gene promoter, and a mammary cell line in which the cell type specific promoter is a MMTV gene promoter. The conditional oncogene, transforming gene or immortalising gene is preferably a SV40tsA58 gene.
    Type: Grant
    Filed: October 16, 1998
    Date of Patent: November 30, 2004
    Inventors: Philip Spencer Rudland, Barry Roger Barraclough, Iain Charles Kilty, Barry Robert Davies, Guenter Schmidt